[High-dose enzyme-substitution therapy in digestive disorders].
A new highly effective enzyme-substituting product (Combizym forte) was tested clinically on 62 patients suffering from digestive insufficiency to ascertain the improvements of the complaints pain, nausea, meteorism, diarrhea and obstipation as well as the tolerance. 88,7% of the cases were free from complaints within about 14 days of treatment. Three patients had diarrhea; no other sidereactions were observed. Apart from the high enzymatic activity of Combizym forte, the absence of Fel tauri is noteworthy as it allows to increase doses considerably. The demonstration of the therapeutic action of Combizym forte by examinations of the stools and enzyme-chemical measurements will be the subject of another series of tests (2nd information).
D000328:Adult; D000368:Aged; D000681:Amylases / Q000494:pharmacology / Q000627:therapeutic use; D002480:Cellulase / Q000494:pharmacology / Q000627:therapeutic use; D004063:Digestion / Q000187:drug effects*; D004338:Drug Combinations; D004341:Drug Evaluation; D057487:Enzyme Therapy; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D006801:Humans; D008049:Lipase / Q000494:pharmacology / Q000627:therapeutic use; D008875:Middle Aged; D010194:Pancreatin / Q000494:pharmacology / Q000627:therapeutic use; D010447:Peptide Hydrolases / Q000494:pharmacology / Q000627:therapeutic use
D004338:Drug Combinations; D010194:Pancreatin; D008049:Lipase; D000681:Amylases; D002480:Cellulase; D010447:Peptide Hydrolases
Hochdosierte Enzym-Substitutionstherapie bei Verdauungsstoörungen. Vorlüfige Mitteilung.